Coronavirus Notebook: WHO Says Extra Vaccine Boosters Confer Some Limited Benefits, Emergex & Zosano Link Up On T Cell Vaccine Patch
Executive Summary
International regulators have issued an updated statement on the benefits and safety of COVID-19 vaccines for use by health professionals, while the UK BioIndustry Association has welcomed a MAb licensing deal between AstraZeneca and UK-based biotech firm RQ Bio.
You may also be interested in...
AstraZeneca Buys Into COVID-19 Antibodies From Newly Launched RQ Bio
The big pharma company and its new partner both expect demand to continue for pre-exposure prophylaxis antibody therapies, for COVID-19 and beyond.
Countries To Discuss Pandemic Treaty Next Year Amid Industry Concern
A World Health Organization negotiating body has agreed to develop a “zero draft” of the proposed pandemic treaty for discussion at a meeting of WHO member states in February next year. But the international pharmaceutical industry has reiterated its concerns about some of the proposals being put forward.
EU Health Ministers Want Changes to COVID-19 Vaccine Contracts Amid Oversupply Concerns
EU member states are calling for a formal approach to making vaccine procurement agreements more flexible, saying that any further delay will “undermine the trust of society in vaccination and vaccines.”